Home
About
Overview
Sharing Data
ORCID
Help
History (11)
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Mating preferences of selfish sex chromosomes.
Clinical evidence of inflammation driving secondary brain injury: a systematic review.
A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis.
See All 11 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis.
Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum. 2005 Oct 15; 53(5):788-91.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Dermatologic Agents
Female
Humans
Infliximab
Male
Middle Aged
Retrospective Studies
Sarcoidosis
Treatment Outcome
Tumor Necrosis Factor-alpha
authors with profiles
James J. Curran